Here is the recently published Cleveland Clinic publication on the ASSURE trial.

Effect of the BET Protein Inhibitor, RVX-208, on Progression of Coronary Atherosclerosis: Results of the Phase 2b, Randomized, Double-Blind, Multicenter, ASSURE Trial.

I don't have access to the full text, but one can tell just from the abstract that it is only focused on the apoAI/HDL/PAV/TAV data for the placebo vs. RVX-208 groups with no post-hoc analysis for diabetes, hsCRP or statin type. And I don't see MACE mentioned in the abstract. So really this is nothing more than just a peer-reviewed published version of the data we've known about for over 2 years. Yawn. Old news.

Interestingly, I don't recall SUSTAIN ever being published on. Don did mention in one of the recent presentations (R&R I think) that two impressive publications are due out early next year, so perhaps SUSTAIN trial will be wrapped into some of the publications based on the post-hoc analysis of ASSURE and SUSTAIN.

Another paper also came out entitled "An evaluation of RVX-208 for the treatment of atherosclerosis," though I don't have access to the full text for this one either. It seems to be more of the short review type of article.

Best,

BDAZ